Brought to you by 
Cellectis nets $212.3mm through Nasdaq Global Market IPO
26 Mar 2015
Executive Summary
French cancer immunotherapies firm Cellectis SA netted $212.3mm through its initial public offering of 5.5mm American Depositary Shares (representing 5.5mm ordinary shares) at $41.50 each on the Nasdaq Global Market. The company originally planned to sell 3.5mm ADSs; it went public on the Alternext market of Paris’ Euronext in 2007.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Genomics-Proteomics
-
Molecular Diversity
- Natural Products
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cellectis nets $212.3mm through Nasdaq Global Market IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice